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Key points 
This study provides an estimate of the total economic burden of HIV infections to public health 
insurance in France. This disease cost remains high (€1,370 million annually), and we suggest 
ways to reduce it through a study of associated factors, as well as associated mortality. The 
identification of high-cost patient profiles is enabled by a machine learning algorithm.  
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ABSTRACT 
Background: The objective is to characterise the economic burden to the healthcare system 
of people living with HIV (PLWHIV) in France and to help decision makers in identifying 
risk factors associated with high-cost and high mortality profiles. 
Design and Methods: The study is a retrospective analysis of PLWHIV identified in the 
French National Health Insurance database (SNDS). All PLWHIV present in the database in 
2013 were identified.  All healthcare resource consumption from 2008 to 2015 inclusive was 
documented and costed (for 2013 to 2015) from the perspective of public health insurance. 
High-cost and high mortality patient profiles were identified by a machine learning algorithm.  
Results: In 2013, 96,423 PLWHIV were identified in the SNDS database, including 3,373 
incident cases. Overall, 3,224 PLWHIV died during the three-year follow-up period (mean 
annual mortality rate: 1.1%). The mean annual per capita cost incurred by PLWHIV was 
€ 14,223, corresponding to a total management cost of HIV of € 1,370 million in 2013. The 
largest contribution came from the cost of antiretroviral medication (M€ 870; 63%) followed 
by hospitalisation (M€ 154; 11%). The costs incurred in the year preceding death were 
considerably higher. Four specific patient profiles were identified for under/over-expressing 
these costs, suggesting ways to reduce them. 
Conclusion: Even though current therapeutic regimens provide excellent virological control 
in most patients, PLWHIV have excess mortality. Other factors such as comorbidities, lifestyle 
factors and screening for cancer and cardiovascular disease, need to be targeted in order to 
lower the mortality and cost associated with HIV infection. 
 
Significance for public health 
The authors believe that this study is important in that it provides for the first time an estimate 
of the most impacting factors of the total economic burden of HIV infections to public health 
insurance in France. The approach relies on a state of-the-art machine learning analysis. 
Regarding epidemiological results, although the prevalence and incidence of HIV infections 
in Western European countries are reasonably well documented, there is a paucity of 
information on its economic burden. We suggest ways that the economic burden of HIV (€ 
1,400 million annually to public health insurance), as well as associated mortality, could be 
reduced. The main interest and novelty of the results from a public health perspective is the 
identification of patient profiles at risk of high costs. Such results provide clear and potentially 




In 2013, the number of people living with HIV (PLWHIV) in France was estimated at 
around 153,400 [1], of whom 24,500 were unaware of their HIV status and a further 13,800 
had been diagnosed but were not yet receiving an antiretroviral treatment (ART) [2]. In 2013, 
20,126 PLWHIV were hospitalised at least once for a reason related to their HIV infection [3]. 
Given that combined ART (cART) is lifelong, that complications of HIV infection or cART 
are frequent and that PLWHIV are at increased risk for certain comorbidities, the economic 
burden of HIV infection is currently high and may increase in the future. 
Nonetheless, the extent of this burden remains poorly characterised. A review of the 
literature on economic studies of the management of PLWHIV in five Western European 
countries performed in 2014 highlighted the paucity of the available data and the disparity of 
the findings [4]. Several reasons were put forward to account for this, including small sample 
sizes [5] and incomplete cost assessment. Most of recent economic studies were modelling 
studies, principally evaluating cost-effectiveness of new ARTs [6], assessing the impact of 
early diagnosis of high-risk groups [7,8], or of on-demand pre-exposure prophylaxis [9]. The 
only cost-of-illness study identified, which collected real-world data, measured hospital costs 
only [3], but there are little data to date assessing the global burden of HIV infection [10-12]. 
A consolidated national healthcare database (SNDS) is available in France for health 
economic studies. It includes exhaustive healthcare resource consumption data, covering both 
hospital and community medicine sectors, for all individuals with public National Health 
Insurance (NHI) in France [13]. The SNDS is exhaustive for the NHI and was proven reliable 
to conduct epidemiological studies [13]. The use of machine learning technics to predict 
clinical outcomes from such electronic health records or claim data provides is an ever-
increasing topic of interest for decision makers [14-20]. 
The main objectives of this study were to estimate the annual cost of management of 
PLWHIV at a national level in France. Costs are reimbursed care from the NHI’s perspective. 
The corollary research question was to determine if patient characteristics were linked to 
lower/higher management costs and mortality, and to find such profiles. 
 
DESIGN AND METHOD 
Study Design 
This study is a retrospective analysis of PLWHIV identified in the French NHI database 
(SNDS: Système National des Données de Santé) initiated in 2018. This database covers all 
healthcare consumption by French residents insured by the general NHI regimen which cover 
around 75% of the French population and is representative of the entire population in age and 
gender [13]. Data from other insurance schemes are also available in the SNDS, but not 
exhaustively collected, especially regarding mortality. The study identified all PLWHIV 
recorded in the database in 2013. All healthcare consumption for these individuals was tracked 
backwards since 2008 to identify comorbidities and forwards to 2015. 2008 is the earliest year 
for which fully linked information on healthcare consumption is available. The cost analysis 
was performed from the perspective of the NHI. Mortality was assessed on the three-year 
period 2013-2015 and was compared with standardised mortality rates in the French general 
population1. 
Study population 
The study population consisted of all PLWHIV identified in the database by at least one 
of the following criteria: i) eligibility for long-term disease status (ALD) due to HIV infection 
in 2013, ii) at least two prescriptions for a specific anti-HIV treatment in 2013-2014, iii) HIV 
gene sequencing for drug resistance testing or iv) hospitalisation with a mention of HIV 
infection on the discharge summary. Patients that had not been affiliated with the same general 
insurance fund since 2008 were also excluded as data from other insurances are unavailable. 
Although it lowers the cohort size, it avoids falsely underestimating the primary outcome of 
this study, costs of care, due to long-lasting unrecorded care in patient’s claim history. 
The prevalent population was defined as all eligible subjects in 2013, and an incident 
population as those among them with no HIV-related event recorded before 2013. Individuals 
were excluded if no healthcare resource consumption was recorded between 2013 and 2015 if 
they were <18 years and had been treated with an ART for less than seven weeks (ART for 
six weeks is a recommended prophylaxis in children born to HIV-positive mothers).  
 
 
1Source from the French National Institute of Statistics and Economic Studies: https://www.insee.fr/fr/statistiques/2554599?sommaire=1912926 
Data extraction 
Data were extracted for each eligible patient concerning age, gender, date of death (if 
deceased) and any eligibility for ALD status. All healthcare resource consumption 
(hospitalisations, consultations, medical procedures and tests, and medication) and 
reimbursement (date and amount) over the period between 2008 and 2015 inclusive was 
documented. 
The comorbidities were identified based on either chronic disease identified in hospital 
discharge summaries, ALD status or long-term medication prescription for vascular 
prevention or psychiatric disorders. Pathologies of particular interest in PLWHIV (hepatitis B 
or C infection, non-Hodgkin lymphoma and Kaposi’s sarcoma), as well as opportunistic 
infections potentially attributable to HIV infection, were documented on the basis of ICD-10 
codes in hospital discharge summaries for the period 2008 – 2015 or with ALD status for one 
of these conditions (Supplementary Table 1). 
 
Costing 
Costs were assigned from the French national tariffs applicable in the year of resource 
consumption, and were expressed in euros, updated to 2019-values to take into account 
inflation. Two costs were measured: the annual cost per incident patient, from the inclusion 
date, and the overall reimbursed costs for the calendar year 2013. For hospital stays, a standard 
national tariff was applied based on DRG codes. These standard tariffs include medical and 
related procedures, nursing care, treatments (except specific expensive drugs), food and 
accommodation. 
For the study of factors associated with the annual cost, the focus was to find subgroups 
of patients (= profiles) under-expressing or overexpressing such cost. To strengthen the 
detection of the most prominent profiles, and to provide clear and explainable results to 
decision makers, three arbitrary categories (low, medium, high) were created based on the 
observed cost distribution. Thus, the search for patient profiles was addressed as a 3-class 
classification problem. 
 
Statistical methods - decision tree analysis 
A machine learning model using decision tree analysis was built to study the factors 
associated with the risk of having low/high annual cost of care, using a binary splitting 
decision tree algorithm (scikit-learn library 0.21.2, python 3.7)  [19,21]. The model built itself 
iteratively, starting with the entire cohort (the root, the centre of the sunburst) and first 
searched for the most discriminating variable to divide the cohort into two subgroups (the 
branches, the innermost circle) which segregated as much as possible the target variable (the 
annual cost) into three arbitrary categories (low, medium, high). The resulting tree is 
represented as a “sunburst plot”.  
All variables collected from the SNDS database were considered as potential 
discriminating variables and entered in the algorithm. Fifty-eight individual variables were 
considered, including demographics, socioeconomic variables, comorbidities, pathologies 
related to HIV infection and healthcare resource consumption variables, all listed in the 
Supplementary Table 2. The quality of segregation was estimated by the Gini impurity (the 
lower the Gini, the most discriminating a variable is) [21]. In each following round, each branch 
was split into two further sub-branches using the same procedure (on the sunburst plot, each 
segment of the circle is divided in two sub-segments). Further sub-branches were developed 
until one of three criteria were met, namely when the resulting subgroup corresponded to <1% 
of the original cohort, when the decrease in Gini impurity was minimal (<0.1) or when six 
levels of division from the root had been reached. These criteria prevent the algorithm from 
overfitting the data and ensure concise identified profiles. 
The model was initially built on a random sample of 80% of the study cohort. Its 
performance was then tested on the remaining 20% of the cohort. A decision tree technic was 
chosen, among other machine learning technics, for its capability to perform well on multiclass 
classification, and for the purpose of clarity and interpretability of the results [14,15,22]. 
Then, the association of study variables with mortality (binary outcome) was first 
evaluated using multivariate logistic regression, performed with regularisation to adjust the 
impact estimation of relevant features. Associations were expressed as logit (log odds-ratio) 
functions. Then, a machine learning model was used to find high-risk profiles, similarly to 
costs. The two technics complement each other: the logistic regression emphasizes and 
compares the intensity of risk protector factors, while the decision tree provides actionable 
profiles for decision makers. 
RESULTS 
Incident and prevalent cases of PLWHIV in 2013 
Overall, 126,515 PLWHIV fulfilling the eligibility criteria for the study were identified 
in the SNDS database in 2013. After exclusion of patients who had not been affiliated with 
the same general insurance fund since 2008, 96,423 individuals were available and constituted 
the prevalence population. For 3,373 of these, no HIV-related event was identified before 
2013, and these constituted the incident population (Figure 1). In the incident population, 521 
individuals (15.5%) were at CDC C stage at the time the HIV infection was diagnosed. 
 
 
Figure 1. Study population. 
 
Overall, 93.4% of the prevalent population had been prescribed an ART at least once, in 
most cases a triple cART. The mean age was 47.5 (± 12.0) in the prevalent population and 
39.4 (± 14.2) in the incident population, with the age distribution shifting slightly towards 
older ages in men (48.7 ± 12.0) compared to women (45.1 ± 12.0). Sociodemographic and 
clinical features of the prevalent population are presented in Supplementary Table 3. 
 
Comorbidities 
Overall, 61.9% of the prevalent population were eligible for ALD status because of a 
comorbidity other than HIV. The most frequent of these were chronic liver disease, psychiatric 
disorders and ‘cardiac and neurovascular diseases’ (Supplementary Table 3). Hepatitis B 
infections were identified in 7.0% of individuals and hepatitis C infections in 12.5%. 
Opportunistic infections were identified in 3.4% of individuals. 
 
Cost analysis 
The total cost of management of the 96,423 prevalent PLWHIV was € 1,370 million in 
2013, of which the largest contribution came from the cost of ART (Table 1). The distribution 
of total annual per capita costs of management of HIV between 2013 and 2015 is presented 
in Figure 2. The mean annual per capita cost was € 14,223 ± € 10,800 and the median cost 
€ 12,093 [interquartile range: € 9,000 to € 16,795]. Per capita costs tended to increase with 
age, although a plateau was reached around the ages of 40 to 50 (Supplementary Figure 1). 
Table 1. Total cost of care for HIV by type of expenditure 
Expenditure type Total cost (M€) 
TOTAL € 1,370 
Antiretroviral therapy € 869.8 (63.4%) 
Hospitalisations € 154.3 (11.3%) 
Sick-leave benefit € 116.3 (8.5%) 
Any other medication € 73.2 (5.3%) 
Outpatient visits € 40.7 (3.0%) 
Paramedical support € 20.6 (1.5%) 
Specialist consultations € 19.2 (1.4%) 
Medical devices € 18.2 (1.3%) 
Transportation costs € 18.1 (1.3%) 
Laboratory tests € 16.0 (1.2%) 
General practitioner consultations € 14.5 (1.1%) 
Other outpatient care € 9.6 (0.7%) 
Other HIV-specific medication € 7.1 (0.5%) 
Medical care provided at the patient’s 
home 
€ 1.0 (0.1%) 
 
For the patients who died during the follow-up period (2013-2015), the costs incurred 
in the year before they died were considerably higher, with a mean per capita annual cost of 




Figure 2. Distribution of total annual per capita costs of management of HIV 
(N=96,423). 
 
Variables associated with cost 
To focus on extreme costs, and based on the cost distribution shown on Figure 2, we 
identified the 20% and 80% percentiles. To improve the clarity of results toward public health 
decision makers, the thresholds were set to the closest rounded thousand. It results in three 
categories, namely high (≥€ 18,000), moderate (€ 8,000 – € 18,000) or low (<€ 8,000), which 
were validated by the scientific committee. These thresholds are well suited to the cost 
statistical distribution (right skew) and avoid emphasising outliers. 
Globally, the two principal drivers of cost identified in the decision-tree analysis were 
the number of months without any documented healthcare reimbursement (accounting for 
43% of variation in costs) and hospitalisation (29% of variation) (Table 2). Since healthcare 
resource consumption expressed in volume is expected to covary tightly with cost, it was 
decided to reiterate this analysis excluding these two variables from the model input (dropout 
strategy). This reduction enables the detection of differences among patients without care gaps 
nor hospitalizations. In this reiteration of the model, the four principal cost drivers were the 
number of comorbidities (34% of variation in cost), the duration of HIV treatment before 
inclusion (20%), the first class of cART prescribed (14%) and the number of non-AIDS 
defining infections identified during hospitalisation (14%) (Table 2). Further information 
about four outstanding profiles resulting from this analysis is presented in Figure 3. 
 
Table 2. Variables contributing to the variance in cost (ED: Emergency Department; 
HCC: HealthCare Consumption; HIV: human immunodeficiency virus), evaluated from 
2013 to 2015. The direction of variations due to variables’ contribution is shown in the 
profiles of Figure 3. 
 
 MODEL 1 MODEL 2 
Population evaluated Entire cohort Entire cohort 














Number of comorbidities 12% 34% 
Treatment duration coverage  
(in months) 
10% 20% 
Number of infections 3% 14% 




Number of ED visits - 5% 
6-month gap in HCC (presence) - 4% 
Booster (pharmacokinetic 
enhancers) as part of first-line 
therapy 
2% - 
Number of treatment changes <1% - 
Age at inclusion <1% - 
Number of switches between 
triple therapies 
<1% 4% 
Year HIV diagnosed <1% <1% 
Day hospitalisation <1% - 
 
Profile 1, accounting for 10% of the cohort, was associated with high cost (≥€18,000) 
and characterised by the presence of two or more associated comorbidities, an absence of non-
AIDS defining infections and multiple ART treatment. Profile 2, also associated with high 
cost, accounted for 4% of the cohort and was characterised by the presence of two or more 
associated comorbidities and at least one non-AIDS defining infection. Profile 3 was 
associated with moderate cost (€8,000 to €18,000) and accounted for 61% of the cohort. This 
cohort was characterised by no more than one comorbidity and having a standard ART 
regimen throughout the follow-up. Profile 4, associated with low cost (<€8,000), accounted 




Figure 3. Sunburst plot of variables associated with costs of HIV: 4 profiles identified by 
a machine learning algorithm. 
 
Mortality 
Overall, 3,224 patients of the prevalent population died during the follow-up period 
(1,015 in 2013, 1,144 in 2014 and 1,065 in 2015), corresponding to a mean annual mortality 
rate of 1.1%. Age and gender specific mortality rates in the prevalent population were 
compared with standardised mortality rates in the French general population. Mortality rates 
in HIV individuals from the SNDS were higher than in the general population in all age groups 
(for 2013: 40-44 age group: 6.13 vs 1.38; 45-49: 9.75 vs 2.29; 50-54: 12.66 vs. 3.62). The 
excess mortality in PLWHIV tended to decline over the age of sixty in men (for 2013: 65-69 
age group: 19.48 vs 15.10), whilst it increased in women (for 2013: 65-69 age group: 17.75 vs 
6.60). 
 
Variables associated with mortality 
In the prevalent population, the available variables presenting the strongest associations 
with mortality in the multivariate logistic regression analysis were hospitalisation, older age 
and active cancer (predisposing factors). General practitioner consultations, the number of 
non-AIDS defining infections and periods of ≥6 months without healthcare reimbursement 
were associated with decreased mortality (Figure 4A). For this regression analysis, the area 
under the curve (AUC) of the receiver operating characteristics (ROC) curve was 0.93. 
In the decision tree model, the variables which explained the greatest amount of the 
variance were hospitalisation in the year before death, GP consultations and in-hospital 
resuscitation (Figure 4B). The AUC was 0.93. The decision tree model was reiterated after the 
exclusion of certain variables with an obvious relationship with mortality, namely 
hospitalisation, in-hospital resuscitation, age and ‘no documented health care reimbursement 
for ≥6 months’. In this model, the five variables explaining the most variance were the number 
of GP consultations (48% of variance explained), the number of emergency department visits 
leading to hospitalisation (29%), the number of comorbidities (9%), active cancer (7%) and 
day hospitalisation (3%). The AUC was 0.90. 
 
Figure 4. Variables associated with mortality (top: 4A, regression analysis; bottom: 4B, 
decision tree analysis). First type of cART prescribed refers to the number of associated 
ARTs (e.g., dual therapy, triple therapy, etc.). Result: both models, although different by 
nature (parametric regression and non-parametric decision tree), highlight the strong 
individual roles of the same variables. Variable combinations are found in profiles. 
DISCUSSION 
Study cohort 
This study identified PLWHIV from the SNDS database, which covers all health 
resource consumption by beneficiaries of the French general NHI scheme. During the year 
2013, a ‘footprint’ of HIV infection could be identified for 126,515 individuals in the database. 
This figure can be compared with the estimate of 128,586 individuals with a known HIV 
infection in the total French population in the estimate made previously for the same year 
using only the criterion of eligibility for long-term disability status due to an HIV infection [1]. 
The number of cases can also be compared with the number of individuals hospitalised with 
an HIV infection in 2013, which was 20,216 [3]. This indicates that, at least for France, most 
PLWHIV are not hospitalised every year and that estimations of the burden of HIV based 
solely on hospital data will grossly underestimate the total cost of HIV to NHI. 
The number of incident cases was estimated at 3,373 individuals, which is lower than 
the 6,600 new diagnoses of HIV identified each year [2]. This is explained by the restriction 
to patients at the general NHI regimen (75% of the population), and the filter on patients with 
at least one HIV care management, between 2013 and 2015. In addition, around 10% of HIV-
seropositive individuals in France are not being cared for within the health system [1]. A 
limitation of this study, especially regarding the identification of at-risk profiles, is to exclude 




The mean annual per capita cost incurred by PLWHIV was € 14,278, corresponding to 
a total cost of management of HIV of € 1,370 million. This can be compared, for example, to 
the total cost to the French NHI in 2016 of € 3,440 million for chronic respiratory diseases and 
of € 8,120 million for diabetes [23]. Corresponding mean annual per capita costs were € 929 
for chronic respiratory diseases and € 2,150 for diabetes [23]. Such comparisons indicate that 
although the prevalence of HIV infection (~4/1000 in the French adult population in 2013 [1]) 
is relatively low compared to other medical conditions, its management is relatively costly, 
especially the year prior to death. In comparison, the mean annual per capita cost was $ 38,439 
in the USA for the same period [11]; € 19,103 in Germany from 2006 to 2009; $ 17,352 in 
Canada for 2017. The findings of the present study can be compared with those of a micro-
costing study performed in an HIV care reference centre in the North of France in 2004-2005 
[25], which reported average yearly costs of care of PLWHIV ranging from € 19,240 to 
€ 36,540 according to CD4 count. These costs are much higher than those reported here. This 
difference may potentially be explained firstly by a shift from the in-hospital to the outpatient 
setting for routine monitoring of PLWHIV and secondly to the improved tolerability of ART 
which now engenders less costs related to management of side-effects and monitoring than 
was previously the case [10].  
The principal contributor to the cost incurred by PLWHIV was the cost of ART (61.3% 
of total costs). This outweighs by far the cost of hospitalisations, (12.3% of total costs). This 
finding is consistent with previous suggestions that evaluations of the economic burden of 
HIV infection based solely on hospital-based healthcare resource consumption will largely 
underestimate the total burden [4]. Since this was not a case-control study, it was not possible 
to evaluate how much of the cost was specifically related to the management of HIV [11]. In 
the case of ART, 100% of the cost is supposedly HIV-related. In the case of hospitalisation, a 
previous analysis of the national hospital discharge database in 2013 identified the total cost 
of specific HIV-related hospital management to be € 64 million [3], suggesting that around 
35% of hospital costs incurred by PLWHIV are specifically related to the management of HIV, 
with the remainder being related to management of comorbidities. Nevertheless, the cost of 
ART is expected to decrease in the future. This will be a consequence firstly of the wider 
availability of generic ARTs [6] and secondly of simplification of therapeutic regimens 
through the use of effective and well-tolerated dual therapies or intermittent triple therapies 
[24]. A reduced incidence of HIV infections can also be expected due to more widespread pre-
exposure prophylaxis. 
The evaluation of factors associated with the cost of care of PLWHIV principally 
identified factors that are sources of cost, such as hospitalisation and continuous healthcare 
consumption, as well as the number of comorbidities and the number of non-AIDS defining 
infection leading to hospitalisation. It should, however, be hypothesised that patients 
interrupting their treatment, and thus generate short-term economies to the healthcare system, 
might generate higher costs later on, when they return to the health system after a period of 
uncontrolled viraemia with consequences on immunity and/or HIV resistance. None of the 
sociodemographic variables included into the models were strongly predictive of cost. It might 
suggest that the overall quality of care of management of PLWHIV in France is relatively 
uniform and that there are no large segments of the PLWHIV population which generate a 
disproportionate amount of costs, as intended by national health policies. A limitation of the 
presented machine learning work is to address a 3-class classification problem, for clarity and 
communication purposes toward public health decision makers. Future works could include a 




Around 1,100 deaths of PLWHIV per year were identified. This estimate is consistent 
with the estimate from a national cohort study performed in 2010 of around 1,000 deaths [26]. 
Even though >90% of the study population was taking ART, mortality in PLWHIV was 
slightly higher than in the total population of NHI beneficiaries in the SNDS database for all 
age groups. This excess mortality appeared somewhat higher in women, particularly in the 
>65-year-old age groups. However, this probably reflects the lower mortality rate for women 
compared to men in the general population; the absolute mortality rates in men and women 
with HIV were similar. In an analysis performed in France in 2000 addressing the causes of 
mortality in PLWHIV who were well-controlled by ART [27], the principal causes of death 
were HIV-unrelated cancers, notably lung and liver cancer, cardiovascular disease and HCV-
related liver disease. High rates (>35%) of HCV infections, intravenous drug use and alcohol 
dependence were observed in these patients. In the present study, the global rate of HCV 
infection was 12.5%, reflecting the declining HCV seroprevalence in France (currently <1%) 
[28], and mortality due to this cause may be expected to decrease.  
Concerning variables associated with higher risk of mortality, identified in the multiple 
logistic regression analysis and the decision tree analysis, these were essentially unsurprising 
and included overnight hospitalisation, emergency department visits or in-hospital 
resuscitation and comorbidities, notably cancers. The variables most strongly associated with 
reduced mortality were the number of visits to a general practitioner, the number of non-AIDS 
defining infections and the presence of gaps in reimbursement of healthcare longer than six 
months. Visits to a general practitioner is a difficult variable to interpret, but may be a 
surrogate marker for health awareness and care-seeking behaviour. The number of 
documented non-AIDS defining infections may also be a consequence of care-seeking 
behaviours. Gaps in healthcare reimbursement may be a surrogate marker for patients who 
feel well and do not see any benefit to take a treatment or had adverse effects. Importantly, 
none of the socioeconomic variables, such as markers of social deprivation, were identified as 
being associated with increased mortality. 
Conclusion 
The principal strengths of this cost-of-illness study were that the database covers >75% 
of the French population and includes exhaustive information on all reimbursements for 
healthcare made by the NHI fund. For this reason, the derived cost information can be 
considered regarding the real total cost of healthcare incurred by PLWHIV in France. A light 
limitation is that the HIV infection (defined by serological testing or viraemia) is not explicitly 
documented in the database, and had to be derived from proxy variables (ART prescription, 
screening for ART resistance, eligibility for ALD status based on an HIV infection, or 
hospitalisation with a mention of HIV infection on the discharge summary). Likewise, 
individuals with undiagnosed HIV infections, who account for around 16% of the total 
population of PLWHIV [1], cannot be identified, and cost incurred by these individuals cannot 
be determined. Regarding the estimation of costs, the database contains no information on 
important biological variables such as virological control and immunological markers which 
are the major determinants of long-term overall health and prognosis in PLWHIV. Data from 
the French national HIV registry (FHDH ANRS CO4) indicates that around 90% of patients 
receiving ART in 2013 had undetectable viraemia [1]. Finally, certain older hospitalised 
patients may be discharged to a nursing home, where healthcare consumption and deaths are 
not yet well-linked to the SNDS database. 
In conclusion, we have shown in this analysis at a national level that mortality of 
PLWHIV remains higher than in the general population despite effective antiretroviral 
therapy. The direct medical costs of management of PLWHIV to public NHI in France are, on 
a per capita basis, relatively high compared to other chronic morbidities. Even though current 
ART regimens provide excellent viraemic control in most patients, the cost of therapy is high 
and PLWHIV still have excess mortality and HIV-related hospitalisations. Factors other than 
virological control, such as reducing the burden of comorbidities, addressing lifestyle factors 
such as smoking, and screening for cancers and cardiovascular disease, need to be targeted to 
lower the mortality and cost associated with HIV infection. 
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